Goldman Sachs upgraded Abbvie (NYSE: ABBV) from Buy to Conviction Buy with a price target of $80.00 (from $74.00).Analyst Jami ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE